TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12548324
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single course of corticosteroids (two 12 mg doses of betamethasone given IM 24 hours apart, or four 6 mg doses of dexamethasone given IM 12 hours apart)
Study: 11049894
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) administered in two bolus doses of 10 mg/kg each, plus a continuous infusion of 1.0 mg/kg/h for 10 hours after the first bolus.
Study: 11049894
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) administered as described above.
Study: 28277138
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg carnitine supplements
Study: 20222892
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine (TRESIVAC(R)) containing Leningrad-Zagreb mumps strain
Study: 12152000
Drug: Enfuvirtide 45
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide 45 mg (subcutaneous)
Study: 12152000
Drug: Enfuvirtide 90
Normalized name: enfuvirtide 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide 90 mg (subcutaneous)
Study: 12152000
Drug: Enfuvirtide 180
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide 180 mg (subcutaneous)
Study: 12152000
Drug: Enfuvirtide 90
Normalized name: enfuvirtide 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide 90 mg (intravenous)
Study: 10202343
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP; 800 microg/day)
Study: 10202343
Drug: Inhaled beta2‐agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta2‐agonists alone
Study: 11086
Drug: Cimetidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (4 X 200 mg/d p.o.)
Study: 23473350
Drug: Lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40 mg/d for 2 weeks
Study: 23473350
Drug: Lurasidone 80
Normalized name: lurasidone 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80 mg/d for 2 weeks
Study: 23473350
Drug: Lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2
Study: 23473350
Drug: Lurasidone (flexibly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (flexibly dosed 40-120 mg/d for subsequent 4 weeks)
Study: 17420681
Drug: Intensive cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cognitive-behavioral therapy (CBT) - 14 sessions of daily psychotherapy
Study: 17420681
Drug: Weekly cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cognitive-behavioral therapy (CBT) - 14 sessions of weekly psychotherapy
Study: 17420681
Drug: Intensive cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cognitive-behavioral therapy (CBT)
Study: 17420681
Drug: Weekly cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cognitive-behavioral therapy (CBT)
Study: 15136305
Drug: Moderate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate or severe reductions in GFR (30-59 mL/min per 1.73 m² and <29 mL/min per 1.73 m²)
Study: 15136305
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in GFR of 10 mL/min per 1.73 m²
Study: 15136305
Drug: GFR of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR of approximately 60 to 70 mL/min per 1.73 m²
Study: 9551245
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg once daily for 5 days
Study: 9551245
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg divided into three doses for 5 days
Study: 9551245
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg once daily
Study: 9551245
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg divided into three doses
Study: 7936839
Drug: N-terminal propeptide
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal propeptide of type III procollagen (PIIINP) concentration measured by Fab'-fragment and whole antibody-based RIA assay in cord serum and amniotic fluid
Study: 3215203
Drug: Theophylline elixir
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline elixir
Study: 17068392
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg bid
Study: 27325335
Drug: Bevacizumab (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (lower dose 7.5 mg/kg)
Study: 24735616
Drug: Outpatient cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient cognitive behavioral therapy group
Study: 16042894
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily for up to 5 years
Study: 16042894
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of lamivudine therapy after HBeAg seroconversion
Study: 7852463
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of empiric therapy
Study: 26938920
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLF) 100 mg per day
Study: 21443612
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group 1 (T(1), implant diameter 4.3 mm)
Study: 21443612
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group 2 (T(2), implant diameter 4.8 mm)
Study: 21443612
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group 3 (T(3), implant diameter 5.5 mm)
Study: 21443612
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implant diameter 3.8 mm)
Study: 20813541
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using phthalocyanine derivatives as photosensitizers in group L (liposomes)
Study: 20813541
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) in group L (liposomes)
Study: 20813541
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) in group N (nanoemulsions)
Study: 17003366
Drug: Intensive intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intrathecal chemotherapy (standard-risk patients)
Study: 8636369
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg, twice daily)
Study: 24474180
Drug: Chloroprocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 1.0 mL (Group A)
Study: 24474180
Drug: Chloroprocaine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 0.8 mL (Group B)
Study: 24474180
Drug: Chloroprocaine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 0.6 mL (Group C)
Study: 20308670
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with chemotherapy (EC-T[X])
Study: 20308670
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (HER2-negative tumors treated with the same chemotherapy without trastuzumab)
Study: 12100089
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rizatriptan
Study: 7485936
Drug: PCA +
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA + C (continuous infusion of morphine 1 mg/hr)
Study: 7485936
Drug: PCA (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (normal saline infusion)
Study: 30252061
Drug: DMAU 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAU 400 mg
Study: 30252061
Drug: Control 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 400 mg
Study: 30252061
Drug: DMAU (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAU (various doses: 0, 100, 200, 400 mg)
Study: 28511660
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg once daily for up to 28 days)
Study: 28511660
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets for up to 28 days)
Study: 26091830
Drug: Ropivacaine 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.50% (30 cc) + placebo
Study: 26091830
Drug: Ropivacaine 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 μg/kg
Study: 12837869
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV)
Study: 22496101
Drug: Oral Losec
Normalized name: Losec
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Losec MUPS for a period of 2 months
Study: 22496101
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin C tablet for a period of 2 months
Study: 17335366
Drug: Subgingival chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival chlorhexidine (CHX) varnish administration
Study: 17335366
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene instructions and same-day full-mouth root planing)
Study: 15204012
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg xaliproden
Study: 15204012
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg xaliproden with riluzole
Study: 12226965
Drug: Behavioral strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral strategy to enhance adherence to daily monitoring
Study: 9843529
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (beta-estradiol 2 mg/tablet, 3 tablets/day for 3 days)
Study: 8305322
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment applied twice daily
Study: 3059274
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg/day and Penicillin 3 M UI/day
Study: 3059274
Drug: Cephalothin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin 250 mg, Gentamicin 20 mg, and Bacitracin 150 UI
Study: 24491880
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks
Study: 21396703
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec three times a week (starting dose 20 U per injection)
Study: 21396703
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec once a day (starting dose 10 U; group A)
Study: 21396703
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec once a day (starting dose 10 U; group B)
Study: 21396703
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once a day (starting dose 10 U)
Study: 19905945
Drug: Experimental combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental combined regenerative therapy (ET)
Study: 14628982
Drug: Controlled-release paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release paroxetine (paroxetine CR) up to 50 mg/day
Study: 14628982
Drug: Immediate-release paroxetine
Normalized name: paroxetine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release paroxetine (paroxetine IR) up to 40 mg/day
Study: 10995147
Drug: Combined rectus
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rectus sheath and ilioinguinal blocks with bupivacaine 0.25% with adrenaline 1:400,000, up to 60 ml depending on patient's weight.
Study: 7783888
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (DCA) treatment
Study: 2213636
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg/day) administered at 7 a.m.
Study: 2213636
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg/day) administered at 11 p.m.
Study: 2213636
Drug: Control (light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (light therapy not specified in the abstract)
Study: 352200
Drug: Racemic epinephrine
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic epinephrine 4.5 mg
Study: 352200
Drug: Racemic epinephrine
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic epinephrine 9 mg
Study: 31014369
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Study: 31014369
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS (1 Hz, 20 sessions, delivered twice a day, 5 days a week for 2 weeks)
Study: 28516342
Drug: Oxycodone 10-mg
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10-mg product under fasting conditions
Study: 28516342
Drug: Oxycodone 10-mg
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10-mg product under fed conditions
Study: 25375652
Drug: Desvenlafaxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50 mg/d and 100 mg/d)
Study: 22524834
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus chemotherapy (TP) group (Taxotere 35 mg/m2 once weekly, Cisplatin 20 mg/m2 once weekly)
Study: 24855368
Drug: ERN/LRPT 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT 1 g/20 mg
Study: 19602880
Drug: N-ER 1
Normalized name: (Alginate)n+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-ER 1 g (Niaspan(R))
Study: 17331753
Drug: 2.5% lidocaine/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine/2.5% prilocaine (EMLA) cream
Study: 17331753
Drug: 2.5% lidocaine/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine/2.5% prilocaine (Oraqix) gel
Study: 15672120
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate 1000 mg/day
Study: 15672120
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate 2000 mg/day
Study: 9541154
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day venlafaxine
Study: 9541154
Drug: 225 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg/day venlafaxine
Study: 9541154
Drug: 375 mg/day
Normalized name: estradiol 0.0375 MG/DayTransdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/day venlafaxine
Study: 8014524
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T)
Study: 8014524
Drug: Reconstituted lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted lyophilized PRP-T vaccine
Study: 21204607
Drug: Cetrorelix (CTX)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CTX) 3.0 mg
Study: 18762208
Drug: NHTG2 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHTG2 (4 mg)
Study: 9593024
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (2 doses of whole, killed promastigote vaccine cocktail plus BCG adjuvant)
Study: 9593024
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 doses of BCG only)
Study: 3136608
Drug: All concentrations
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All concentrations of vaccine
Study: 31837276
Drug: Standardised home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised home exercise jaw opening and chewing programmes, and home oral hygiene measures instructed and controlled by a trained dentist.
Study: 28604618
Drug: Trans-resveratrol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-resveratrol (2 × 75 mg/day) for 4 weeks
Study: 27807887
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 4 weeks
Study: 17439539
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 1.5 microm
Study: 17439539
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 2.5 microm
Study: 17439539
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 4.5 microm
Study: 16307696
Drug: Metopimazine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine (15 mg tid) with methylprednisolone (48 mg)
Study: 16307696
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg bid) with methylprednisolone (48 mg)
Study: 11950706
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment in 20 low-HDL subjects
Study: 10710176
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (low doses in the afternoon)
Study: 7628885
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulant treatment after myocardial infarction
Study: 2487802
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg a day
Study: 2487802
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20 mg b.i.d.
Study: 2487802
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg and Nifedipine retard 20 mg once a day
Study: 31629805
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% BID
Study: 25516316
Drug: Turmeric (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (1 g)
Study: 25516316
Drug: Cinnamon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (2 g)
Study: 25516316
Drug: Turmeric (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (1 g) with white bread
Study: 12860337
Drug: Extraamniotic prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraamniotic prostaglandin E2 (PGE2) applied in serial doses of 200 mcg every 2 h up to 20 doses.
Study: 12860337
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin added when fetus was not expelled.
Study: 10923280
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg/day for 12 weeks
Study: 10923280
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg/day for 12 weeks
Study: 8638517
Drug: 5 ppm
Normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ppm hydrogen sulfide (H2S) inhalation
Study: 1433583
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (reimplantation)
Study: 31254596
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 25 mg/day for 3 weeks
Study: 29283177
Drug: UAB criteria
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAB criteria (AVF outflow vein lumen diameter ≥4 mm and blood flow ≥500 mL/min)
Study: 29283177
Drug: NKF criteria
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKF criteria (AVF outflow vein lumen diameter ≥6 mm and blood flow ≥600 mL/min)
Study: 26750378
Drug: Concentrated ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ambient coarse PM (164.2 ± 80.4 μg/m(3))
Study: 20838372
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg kg‐1)
Study: 20838372
Drug: Landiolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.2 mg kg‐1)
Study: 20838372
Drug: Control (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.1 mL kg‐1 saline)
Study: 12153738
Drug: Dexamethasone (DEX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (DEX), 0.1 mg twice daily for 3 days